Showing 3211-3220 of 3844 results for "".
- Hydrafacial X Omorovicza Collab: Advanced Skin Renewal Boosterhttps://practicaldermatology.com/news/hydrafacial-x-omorovicza-collab-advanced-skin-renewal-booster/2461569/The Beauty Health Company’s Hydrafacial is rolling out a new booster co-created with Hungarian skincare brand Omorovicza. The booster, available immediately to Hydrafacial providers in North America and EMEA, leverages Omorovicza’s patented Healing Concentrate for a mo
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- Cutera Launches Rewards Program for High-Volume AviClear Usershttps://practicaldermatology.com/news/cutera-launches-rewards-program-for-high-volume-aviclear-users/2461548/Practices in the United States and Canada using AviClear will now have access to more perks. Cutera announced that it will be launching a rewards program for AviClear practices designed to reinforce a partnership approach with practices with improved profitability, e
- Murad, Active Minds Join Forces to Help Young Adults Stress Lesshttps://practicaldermatology.com/news/murad-active-minds-join-forces-to-help-young-adults-stress-less/2461543/Murad is partnering with Active Minds, a nonprofit supporting mental health awareness and education for young adults. In 2003, Dr. Murad coined the term 'cultural stress', the day-to-day stress of modern living as a major factor contributing to the chronic exhau
- Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Study Causes of Atopic Dermatitis and Food Allergyhttps://practicaldermatology.com/news/mount-sinai-researchers-awarded-12-million-nih-grant-to-create-a-center-to-study-causes-of-atopic-dermatitis-and-food-allergy/2461520/Mount Sinai researchers have been awarded $12 million over 5 years by the National Institutes of Health (NIH) to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis, according to a news release. The Systems Biology of Early Ato
- Allergan Aesthetics Rolls Out Juvéderm Volux XChttps://practicaldermatology.com/news/allergan-aesthetics-rolls-out-juvederm-volux-xc/2461507/Allergan Aesthetics' Juvéderm Volux XC is now available at aesthetic practices nationwide. The filler is approved for patients older than 21 with moderate to severe loss of jawline definition. "With 40% of aesthetically-aware consumers considering tre
- ASA Earns Candid's Platinum Seal of Transparencyhttps://practicaldermatology.com/news/asa-earns-candids-platinum-seal-of-transparency/2461505/The American Skin Association (ASA) recieved Candid's Platinum Seal of Transparency, previously recognized as GuideStar's Platinum Seal of Transparency. Candid collects nonprofit data, and this designation demonstrates that ASA is an organization focused on measuring progr
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- Enrollment Complete for Journey’s Phase 3 Trials of DFD-29 in Papulopustular Rosaceahttps://practicaldermatology.com/news/enrollment-complete-for-journeys-in-phase-3-trials-of-dfd-29-in-papulopustular-rosacea/2461492/Journey Medical Corporation’s Phase 3 clinical trial program of DFD-29 for papulopustular rosacea is now fully enrolled. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the D
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D arr